Genovis AB (GENO) Fair Value & Analysis
Healthcare · SE · Market cap 1.3B SEK
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from kr 10.58 to kr 7.83 (−26.0%) since Jun 23, 2026. Share price −4.2% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 15.46 – kr 28.22 · fair‑value band kr 5.87 – kr 9.78 · the kr 18.52 price screens above the kr 7.83 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Genovis AB (GENO) currently trades at kr 18.52, while our model-based Fair Value estimate is kr 7.83 — implying the stock looks roughly 57.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Genovis AB generated revenue of 131M SEK at a net margin of 18.5%. Revenue grew 3.5% year over year. It earns a return on equity of 9.5%. The balance sheet holds a net cash position of 23.4M SEK. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Genovis AB reported revenue of kr 129M in FY2025 versus kr 93.0M in FY2021, a compound +8.5%/yr. Reported net income was kr 23.5M in FY2025, compounding −1.3%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Genovis AB (GENO) undervalued?
What is the fair value of GENO?
What is the quality score of GENO?
What is the revenue of Genovis AB (GENO)?
What is the net profit margin of GENO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.